Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy

OBJECTIVES: There is a need to remove excess iron with iron chelation therapy (ICT) to avoid the serious clinical sequelae associated with iron overload in patients with beta thalassemia major (BTM) and sickle cell anemia (SCA). Due to the effects of the diseases and their treatments, ICT is still a...

Descripción completa

Detalles Bibliográficos
Autores principales: Senol, Sefika Pinar, Tiftik, Eyup Naci, Unal, Selma, Akdeniz, Aydan, Tasdelen, Bahar, Tunctan, Bahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804405/
https://www.ncbi.nlm.nih.gov/pubmed/27057126
http://dx.doi.org/10.4103/0976-0105.177706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804405/
https://www.ncbi.nlm.nih.gov/pubmed/27057126
http://dx.doi.org/10.4103/0976-0105.177706

Ejemplares similares